Prosecution Insights
Prosecution Insights
6 pending office actions • 3 clients • 6 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| §102 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.3% |
| CHAO, ALLEN | 1 | 80.0% | +0.0% |
| TORRES, ALICIA M | 1 | 73.7% | +17.6% |
| WELLS, LAUREN QUINLAN | 1 | 45.9% | +60.0% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 55.6% | +21.2% |
| SONG, JIANFENG | 1 | 56.0% | +33.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284531 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | CHAO, ALLEN | 26d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276837 | SINGLE OPERATOR SEED PLANTING APPARATUSES, SYSTEMS, AND METHODS OF USE | TORRES, ALICIA M | 121d overdue |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | WELLS, LAUREN QUINLAN | 26d overdue |
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | CHANDRAKUMAR, NIZAL S | — |
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| 17627112 | COMPOSITION AND METHOD OF TREATING BACTERIAL AND VIRAL PATHOGENS IN PLANTS | SONG, JIANFENG | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Bristol-Myers Squibb | 4 |
| Brooklyn Bridge to Cambodia | 1 |
| Greening Be Gone, LLC | 1 |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1625 | 1 |
| 3671 | 1 |
| 1621 | 1 |
| 1613 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | Bristol-Myers Squibb Company | CHANDRAKUMAR, NIZAL S | 1625 | DP | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18284531 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | Bristol-Myers Squibb Company | CHAO, ALLEN | 1622 | §102 | Non-Final OA | 26d overdue | Pending | Sep 27, 2023 |
| 18276837 | SINGLE OPERATOR SEED PLANTING APPARATUSES, SYSTEMS, AND METHODS OF USE | Brooklyn Bridge To Cambodia, Inc. | TORRES, ALICIA M | 3671 | §103 | Final Rejection | 121d overdue | Pending | Aug 10, 2023 |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | Bristol-Myers Squibb Company | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | 26d overdue | Pending | Mar 16, 2023 |
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | Bristol-Myers Squibb Company | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Final Rejection | — | Pending | Mar 01, 2022 |
| 17627112 | COMPOSITION AND METHOD OF TREATING BACTERIAL AND VIRAL PATHOGENS IN PLANTS | Greening Be Gone, LLC | SONG, JIANFENG | 1613 | §103 | Final Rejection | — | Pending | Jan 13, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial